Gilead Sciences Inks $247M Deal For HIV Antitrust Claims
By Matthew Perlman · August 10, 2023, 5:32 PM EDT
Gilead has agreed to pay direct purchasers of its HIV medications $246.8 million, ending claims the pharmaceutical company cut a deal with Teva to delay generic versions after reaching an initial...
To view the full article, register now.